TP53 and neoplasm: Treatment of tumor-bearing mice with the DMAPAPA-chitosan/p53 system resulted in significant inhibition of tumor growth (inhibitory rate of 59.0% vs. control group) and a decrease in tumor mass, indicating the platform’s potential for solid tumor therapy due to its increased tumor penetration and efficient in vivo transfection [248].